Abstract
Current chemotherapeutics are characterized by efficient tumor cell-killing and severe side effects mostly derived from off-target toxicity. Hence targeted delivery of these drugs to tumor cells is actively sought. We previously demonstrated that poly(ethylene glycol)-functionalized carbon nanovectors are able to sequester paclitaxel, a widely used hydrophobic cancer drug, by simple physisorption and thereby deliver the drug for killing of cancer cells. The cell-killing when these drug-loaded carbon nanoparticles were used was equivalent to when a commercial formulation of paclitaxel was used. Here we show that by further mixing the drug-loaded nanoparticles with Cetuximab, a monoclonal antibody that recognizes the epidermal growth factor receptor (EGFR), paclitaxel is preferentially targeted to EGFR+ tumor cells in vitro. This supports progressing to in vivo studies. Moreover, the construct is unusual in that all three components are assembled through noncovalent interactions. Such noncovalent assembly could enable high-throughput screening of drug/antibody combinations.
Original language | English (US) |
---|---|
Pages (from-to) | 6643-6650 |
Number of pages | 8 |
Journal | ACS Nano |
Volume | 5 |
Issue number | 8 |
DOIs | |
State | Published - Aug 23 2011 |
Keywords
- drug delivery
- nanovectors
- noncovalent
- paclitaxel
- targeted
ASJC Scopus subject areas
- General Materials Science
- General Engineering
- General Physics and Astronomy